Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

• Status: Completed
• Trial end date: 2006-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMD Serono

Criteria

Inclusion Criteria:

• The participant is an out-patient

• The participant presents with a diagnosis of idiopathic Parkinson's disease

• Prior therapy with all registered Parkinsonian medication is allowed

Exclusion Criteria:

• (For female participants) The participant is pregnant or lactating

• The participant is participating in another clinical study or has done so within the past 30 days

• The participant has received neurosurgical intervention related to Parkinson's disease

• The participant has relevant renal impairment

• The participant has relevant hepatic impairment

• The participant is suffering from any dementia or psychiatric illness

• The participant has a history of allergic asthma